We are investigating the fairness of the sale of scPharmaceuticals, Inc. (Nasdaq: SCPH) (“SCPH”) to MannKind Corporation (“MannKind”) for $5.35 per share in cash, plus one non-tradable contingent value right (“CVR”) per share offering milestone-based payments of up to $1.00 per share.
As detailed below, the sales price is below the price targets for SCPH of multiple Wall Street analysts covering SCPH prior to the announcement (source: TipRanks).
If you remain a SCPH shareholder and question the fairness of the price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On August 25, 2025, SCPH announced that it had agreed to be sold to MannKind for $5.35 per share in cash, plus one non-tradable CVR per share offering milestone-based payments of up to $1.00 per share.
Notably, as per TipRanks, the sales price is below the price targets for SCPH of multiple Wall Street analysts covering SCPH prior to the announcement, including:
- $25.00 set by Stacy Ku of TD Cowen
- $18.00 set by Douglas Tsao of H.C. Wainwright
- $13.00 set by Glen Santangelo of Jefferies
- $12.00 set by Chase Knickerbocker of Craig-Hallum
“Given the low sales price, we are investigating whether the SCPH Board of Directors acted in the best interests of SCPH shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to SCPH shareholders, and whether all material information regarding the transaction has been fully disclosed.”